Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Non Operating Income (2016 - 2024)

Historic Non Operating Income for Ascendis Pharma A (ASND) over the last 13 years, with Q4 2024 value amounting to $88.0 million.

  • Ascendis Pharma A's Non Operating Income rose 11918.87% to $88.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $181.4 million, marking a year-over-year increase of 6382.33%. This contributed to the annual value of $88.0 million for FY2024, which is 11918.87% up from last year.
  • Ascendis Pharma A's Non Operating Income amounted to $88.0 million in Q4 2024, which was up 11918.87% from $40.1 million recorded in Q4 2023.
  • Over the past 5 years, Ascendis Pharma A's Non Operating Income peaked at $88.0 million during Q4 2024, and registered a low of $17.3 million during Q4 2020.
  • Moreover, its 5-year median value for Non Operating Income was $28.8 million (2022), whereas its average is $39.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Non Operating Income soared by 219377.2% in 2020, and later soared by 1746.66% in 2022.
  • Over the past 5 years, Ascendis Pharma A's Non Operating Income (Quarter) stood at $17.3 million in 2020, then surged by 41.5% to $24.5 million in 2021, then grew by 17.47% to $28.8 million in 2022, then skyrocketed by 39.49% to $40.1 million in 2023, then surged by 119.19% to $88.0 million in 2024.
  • Its Non Operating Income was $88.0 million in Q4 2024, compared to $40.1 million in Q4 2023 and $28.8 million in Q4 2022.